Literature DB >> 10527849

Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.

E van Beek1, E Pieterman, L Cohen, C Löwik, S Papapoulos.   

Abstract

Bisphosphonates (Bps), inhibitors of osteoclastic bone resorption, are used in the treatment of skeletal disorders. Recent evidence indicated that farnesyl pyrophosphate (FPP) synthase and/or isopentenyl pyrophosphate (IPP) isomerase is the intracellular target(s) of bisphosphonate action. To examine which enzyme is specifically affected, we determined the effect of different Bps on incorporation of [(14)C]mevalonate (MVA), [(14)C]IPP, and [(14)C]dimethylallyl pyrophosphate (DMAPP) into polyisoprenyl pyrophosphates in a homogenate of bovine brain. HPLC analysis revealed that the three intermediates were incorporated into FPP and geranylgeranyl pyrophosphate (GGPP). In contrast to clodronate, the nitrogen-containing Bps (NBps), alendronate, risedronate, olpadronate, and ibandronate, completely blocked FPP and GGPP formation and induced in incubations with [(14)C]MVA a 3- to 5-fold increase in incorporation of label into IPP and/or DMAPP. Using a method that could distinguish DMAPP from IPP on basis of their difference in stability in acid, we found that none of the NBps affected the conversion of [(14)C]IPP into DMAPP, catalyzed by IPP isomerase, excluding this enzyme as target of NBp action. On the basis of these and our previous findings, we conclude that none of the enzymes up- or downstream of FPP synthase are affected by NBps, and FPP synthase is, therefore, the exclusive molecular target of NBp action. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527849     DOI: 10.1006/bbrc.1999.1499

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  102 in total

1.  Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures.

Authors:  Yuwei Wang; Alexandra Panasiuk; David W Grainger
Journal:  Mol Pharm       Date:  2011-01-21       Impact factor: 4.939

Review 2.  [Bisphosphonates in adjuvant therapy of breast cancer].

Authors:  Heinz Jürgen Deuber; Friedrich Theiss
Journal:  Med Klin (Munich)       Date:  2010-09-28

3.  Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.

Authors:  Vidyalakshmi Sethunath; Huizhong Hu; Carmine De Angelis; Jamunarani Veeraraghavan; Lanfang Qin; Nicholas Wang; Lukas M Simon; Tao Wang; Xiaoyong Fu; Agostina Nardone; Resel Pereira; Sarmistha Nanda; Obi L Griffith; Anna Tsimelzon; Chad Shaw; Gary C Chamness; Jorge S Reis-Filho; Britta Weigelt; Laura M Heiser; Susan G Hilsenbeck; Shixia Huang; Mothaffar F Rimawi; Joe W Gray; C Kent Osborne; Rachel Schiff
Journal:  Mol Cancer Res       Date:  2019-08-16       Impact factor: 5.852

Review 4.  [Introduction to bisphosphonates. History and functional mechanisms].

Authors:  H Fleisch
Journal:  Orthopade       Date:  2007-02       Impact factor: 1.087

Review 5.  Mammalian hibernation as a model of disuse osteoporosis: the effects of physical inactivity on bone metabolism, structure, and strength.

Authors:  Meghan E McGee-Lawrence; Hannah V Carey; Seth W Donahue
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-10-08       Impact factor: 3.619

6.  Bisphosphonate-Generated ATP-Analogs Inhibit Cell Signaling Pathways.

Authors:  Satish R Malwal; Bing O'Dowd; Xinxin Feng; Petri Turhanen; Christopher Shin; Jiaqi Yao; Boo Kyung Kim; Noman Baig; Tianhui Zhou; Sandhya Bansal; Rahul L Khade; Yong Zhang; Eric Oldfield
Journal:  J Am Chem Soc       Date:  2018-06-05       Impact factor: 15.419

7.  Synthesis and Immunomodulatory Activity of Fluorine-Containing Bisphosphonates.

Authors:  Satoshi Mizuta; Mohammed S O Tagod; Masashi Iwasaki; Yoichi Nakamura; Hiroaki Senju; Hiroshi Mukae; Craig T Morita; Yoshimasa Tanaka
Journal:  ChemMedChem       Date:  2019-01-25       Impact factor: 3.466

8.  Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.

Authors:  Sho-ichi Yamagishi; Riichiro Abe; Yosuke Inagaki; Kazuo Nakamura; Hiroshi Sugawara; Daisuke Inokuma; Hideki Nakamura; Tadamichi Shimizu; Masayoshi Takeuchi; Akihiko Yoshimura; Richard Bucala; Hiroshi Shimizu; Tsutomu Imaizumi
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

9.  Water-soluble polymer-drug conjugates for combination chemotherapy against visceral leishmaniasis.

Authors:  Salvatore Nicoletti; Karin Seifert; Ian H Gilbert
Journal:  Bioorg Med Chem       Date:  2010-03-02       Impact factor: 3.641

10.  Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.

Authors:  Nicoletta Bivi; Milena Romanello; Richard Harrison; Ian Clarke; David C Hoyle; Luigi Moro; Fulvia Ortolani; Antonella Bonetti; Franco Quadrifoglio; Gianluca Tell; Daniela Delneri
Journal:  Genome Biol       Date:  2009-09-10       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.